GILD Stock Recent News
GILD LATEST HEADLINES
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.
Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europe for PBC treatment could boost the Liver Disease portfolio, despite risks tied to confirmatory trials. SUNLENCA could become the first twice-yearly HIV prevention medication, pending regulatory approvals in the U.S. and Europe, potentially enhancing the HIV franchise.
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline. The post Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding appeared first on Investor's Business Daily.
Three U.S. bigwigs flying high year to date with more upside are GILD, GE and PGR.
Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is under review by the Trump administration, and the Health and Human Services Department could significantly cut funds.
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.